CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 40 target
Drug / intervention
HLX208drug
Likely dose
HLX208 450mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05092802
NCT05092802Phase 2Unknown
CompareCT.gov

An Open-label, Multicenter Phase II Clinical Study to Evaluate Safety, Efficacy and PK of HLX208 for Refractory Primary Brain Tumors With BRAF Mutation

Shanghai Henlius Biotech·interventional·Posted Oct 26, 2021·Updated May 3, 2022

In Brief

A Phase 2 clinical trial evaluating HLX208 for Brain Tumor, Primary. Targeting 40 participants across 1 site.

Detailed Summary

An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for refractory primary brain tumors with BRAF mutation

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Tumor, Primary
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
20222023202420252026
First PostedOct 26, 2021
Enrollment StartDec 23, 2021
Primary CompletionMay 30, 2023
Study CompletionMay 30, 2024
TodayJul 1, 2026
Enrollment to primary: 1.4 yearsPosted 4.7 years ago

Interventions

HLX208drug

450mg bid po